Attrition and non-compliance in secondary stroke prevention trials

Neuroepidemiology

Volumn 23, Issue 1-2, 2004, Pages 61-66

  Gencheva, E ^a,b   Sloan, M ^a   Leurgans, S ^a   Raman, R ^a   Harris, Y ^c   Gorelick, P ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b Center for Stroke Research   (United States)

^c NONE

Author keywords

Attrition rate; Clinical trials; Lost to follow up; Withdrawal

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PROPHYLAXIS; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

AGED; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; SELECTION BIAS; TREATMENT REFUSAL;

EID: 0942279486     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073976     Document Type: Review

References (35)

1. Cook DJ, Guyatt GH, Laupacis A, Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992;102:305S-311S.
2. Khan KS, Daya S, Jadad A: The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156:661-666.
3. Colditz GA, Miller JN, Mosteller F: How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989;8:441-454.
4. Miller JN, Colditz GA, Mosteller F: How study design affects outcomes in comparisons of therapy. II: Surgical. Stat Med 1989;8:455-466.
5. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
6. Schulz KF: Randomised trials, human nature, and reporting guidelines. Lancet 1996;348:596-598.
7. Schulz KF: Subverting randomization in controlled trials. JAMA 1995;274:1456-1458.
8. The Standards of Reporting Trials Group: A proposal for structured reporting of randomized controlled trials. JAMA 1994;272:1926-1931.
9. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276:637-639.
10. Schulz KF: The quest for unbiased research: Randomized clinical trials and the CONSORT reporting guidelines. Ann Neurol 1997;41:569-573.
11. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-662.
12. Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. JAMA 2001;285:1992-1995.
13. Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996-1999.
14. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH: Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-2003.
15. Rennie D: CONSORT revised: Improving the reporting of randomized trials. JAMA 2001;285:2006-2007.
16. Richardson D, Leurgans S: Sample size justification in phase III/IV clinical trials. Neuroepidemiology 1998;17:63-66.
17. Hass W, Easton J, for the Ticlopidine Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1988;321:501-507.
18. Gorelick PB, Leurgans S: African American Stroke Prevention Study: Clinical trial design. J Stroke Cerebrovasc Dis 1998;7:426-434.
19. Harris Y, Gorelick PB, Samuels P, Bempong I: Why African Americans may not be participating in clinical trials. J Natl Med Assoc 1996;88:630-634.
20. Gorelick PB, Harris Y, Burnett B, Bonecutter FJ: The recruitment triangle: Reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial: An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc 1998;90:141-145.
21. The American-Canadian Co-Operative Study Group: Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985;16:406-415.
22. Weisberg LA: The efficacy and safety of ticlopidine and aspirin in non-whites: Analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 1993;43:27-31.
23. Gent M, Easton JD, Hashinski VC, Panak E, Sicurella J, Blakely JA, Ellis DJ, Harbison JW, Roberts RS, Turpie AGG, and the CATS Group: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
24. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
25. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
26. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
27. A Swedish Cooperative Study: High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987;18:325-334.
28. ESPS Group: European Stroke Prevention Study. Stroke 1990:21:1122-1130.
29. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
30. Committee CS: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
31. Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR: Medical Epidemiology, ed 3. New York, McGraw-Hill, 2001, pp 141-152.
32. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S-320S.
33. Ellerbeck E, Jencks S, Radford M, Kresowik T, Craig A, Gold J, Krumholz H, Vogel R: Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-1514.
34. Mark D, Naylor C, Hlatky M, Califf R, Topol E, Granger C, Knight J, Nelson C, Lee K, Clapp-Channing N, Sutherland W, Pilote L, Armstrong P: Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994;331:1130-1135.
35. O'Connor G, Quinton H, Traven N, Ramunno L, Dodds T, Marciniak T, Wennberg J for The Cooperative Cardiovascular Project: Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project. JAMA 1999;281:627-633.